Praxis Precision Medicines (NASDAQ:PRAX) versus Sycamore Entertainment Group (OTCMKTS:SEGI) Head to Head Analysis

Praxis Precision Medicines (NASDAQ:PRAX) and Sycamore Entertainment Group (OTCMKTS:SEGI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.

Valuation & Earnings

This table compares Praxis Precision Medicines and Sycamore Entertainment Group”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55 million	76.97	-$123.28 million	($10.27)	-3.18
Sycamore Entertainment Group	N/A	N/A	N/A	N/A	N/A

Sycamore Entertainment Group has lower revenue, but higher earnings than Praxis Precision Medicines.

Insider & Institutional Ownership

67.8% of Praxis Precision Medicines shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 75.5% of Sycamore Entertainment Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Praxis Precision Medicines and Sycamore Entertainment Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	1	0	8	0	2.78
Sycamore Entertainment Group	0	0	0	0	0.00

Praxis Precision Medicines currently has a consensus target price of $123.33, suggesting a potential upside of 277.74%. Given Praxis Precision Medicines’ stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Sycamore Entertainment Group.

Risk and Volatility

Praxis Precision Medicines has a beta of 2.66, meaning that its share price is 166% more volatile than the S&P 500. Comparatively, Sycamore Entertainment Group has a beta of 54.56, meaning that its share price is 5,356% more volatile than the S&P 500.

Profitability

This table compares Praxis Precision Medicines and Sycamore Entertainment Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	-9,409.22%	-54.86%	-50.52%
Sycamore Entertainment Group	N/A	N/A	N/A

About Praxis Precision Medicines

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

About Sycamore Entertainment Group

Sycamore Entertainment Group, Inc., a diversified entertainment company, which specializes in the acquisition, marketing, and worldwide distribution of feature-length motion pictures. The company is based in Seattle, Washington.